USNA Usana Health Sciences (USNA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Medicinal chemicals & botanical products · CIK 0000896264
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
82
13F, latest reported quarter
Conversions, 180 days
16
Codes C/M, not in net · no price filed
What the filings say about USNA
Insiders, 180 days
-$619.0K net sold
6 sellers · 0% of sales under a 10b5-1 plan
Usana Health Sciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, USANA HEALTH SCIENCES INC insiders sold a net $619.0K of stock across 116 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Jun 15, 2026.
- 4 other insiders sold within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF COMMERCIAL OFFICER Neidig Brent sold about $97.3K of USNA on Jun 16, 2026; 4 other insiders sold within 30 days and 82 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Jun 12, 2026.
- The trade is 18.2% of the 5,002 shares held after it.
- 4 other insiders sold within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF COMMERCIAL OFFICER Neidig Brent sold about $18.2K of USNA on Jun 15, 2026; 4 other insiders sold within 30 days and 82 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Mar 12, 2025.
- The trade is 27.1% of the 5,911 shares held after it.
- 4 other insiders sold within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF COMMERCIAL OFFICER Neidig Brent sold about $32.3K of USNA on Jun 12, 2026; 4 other insiders sold within 30 days and 82 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on May 28, 2026.
- 4 other insiders sold within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CHIEF PEOPLE OFFICER Jones Paul A. sold about $102.9K of USNA on Jun 8, 2026; 4 other insiders sold within 30 days and 82 funds added in the latest 13F quarter.Context
- 8 earlier Form 4 trades (code P or S) here by this insider (8 sales), the last on Oct 31, 2025.
- The trade is 57.9% of the 4,230 shares held after it.
- 5 other insiders sold within 30 days.
- 82 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fleming John Turman sold about $43.9K of USNA on Jun 1, 2026; 5 other insiders sold within 30 days and 82 funds added in the latest 13F quarter.116 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$619.0K over 180 days
below 58% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
82 funds bought in last quarter
more than 61% of Pharma & Biotech
Revenue
+8.3% year over year
more than 57% of Pharma & Biotech
Margin
1.2% net margin
more than 74% of Pharma & Biotech
Buybacks
$27.5M repurchased, FY to 2026-01-03
below 53% of Pharma & Biotech
Short interest
7.8% of the float short (float per yahoo 2026-10-27) · 4.4 days to cover · settled 2026-10-15
below 53% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 9 in the prior 90
Why it matters
The absence is the signal: 9 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch USNA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-31.8%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns USNA: institutional holders (13F)
13F holdings, latest reported quarter
1,620,148 sh
$34.6M
1,554,189 sh
$33.2M
1,205,587 sh
$25.7M
958,520 sh
$20.5M
837,426 sh
$17.9M
Congress trades in USNA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
USNA planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
USNA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Acquirers Small and Micro Deep Value ETF
$249.7K position · as of 2026-05-31
1.0%
Pzena Small Cap Value Fund
$799.2K position · as of 2026-05-31
0.9%
Ultra-Small Company Fund
$322.4K position · as of 2026-06-30
0.3%
Royce Quant Small-Cap Quality Value ETF
$84.8K position · as of 2026-06-30
0.3%
Ultra-Small Company Market Fund
$427.0K position · as of 2026-06-30
0.3%
First Trust Active Factor Small Cap ETF
$241.7K position · as of 2026-05-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr.Guest
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2020
$3.9M
$6.0M
$1.6M
n/a
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. This filer reported no return figures.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $619.0K sold by insiders over 180 days, 82 funds added last quarter. Each figure is a federal filing, dated the day it went public.
USNA financials
Revenue growth
+8.3%
XBRL, annual
Net margin
1.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$913.4M
four quarters, 2025-06-29 to 2026-07-04
Revenue, TTM USNA
| FY Jan 2026 | $925.3M |
| FY Dec 2024 | $854.5M |
| FY Dec 2023 | $921.0M |
| FY Dec 2022 | $998.6M |
| FY Jan 2022 | $1.2B |
| Jul 2026 | $223.3M |
| Apr 2026 | $250.2M |
| Jan 2026 | $226.2M |
| Sep 2025 | $213.7M |
| Jun 2025 | $235.8M |
| Mar 2025 | $249.5M |
| Dec 2024 | $213.6M |
| Sep 2024 | $200.2M |
At each fiscal year end
Single quarter
Net margin, TTM
-2.4%
net income over revenue, 2025-06-29 to 2026-07-04
Net margin, TTM USNA
| FY Jan 2026 | +1.2% |
| FY Dec 2024 | +4.9% |
| FY Dec 2023 | +6.9% |
| FY Dec 2022 | +6.9% |
| FY Jan 2022 | +9.8% |
| Jul 2026 | -9.6% |
| Apr 2026 | +3.0% |
| Jan 2026 | -0.8% |
| Sep 2025 | -3.1% |
| Jun 2025 | +4.1% |
| Mar 2025 | +3.8% |
| Dec 2024 | +2.1% |
| Sep 2024 | +5.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$15.9M
operating cash flow minus capex, 2025-06-29 to 2026-07-04
Free cash flow, TTM USNA
| FY Jan 2026 | $8.5M |
| FY Dec 2024 | $50.9M |
| FY Dec 2023 | $56.1M |
| FY Dec 2022 | $93.5M |
| FY Jan 2022 | $108.5M |
| Jul 2026 | $20.2M |
| Apr 2026 | $7.1M |
| Jan 2026 | -$6.2M |
| Sep 2025 | -$5.2M |
| Jun 2025 | $7.2M |
| Mar 2025 | $12.7M |
| Dec 2024 | $4.0M |
| Sep 2024 | $27.1M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity USNA
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Jan 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt USNA
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Jan 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-4.2%
TTM net income over average of 2025-06-28 and 2026-07-04
Return on equity USNA
| FY Jan 2026 | +2.0% |
| FY Dec 2024 | +8.2% |
| FY Dec 2023 | +13.7% |
| FY Dec 2022 | +16.7% |
| FY Jan 2022 | +27.8% |
| Jul 2026 | -4.2% |
| Apr 2026 | +1.7% |
| Jan 2026 | +2.0% |
| Sep 2025 | +3.2% |
| Jun 2025 | +6.5% |
| Mar 2025 | +6.8% |
| Dec 2024 | +8.2% |
| Sep 2024 | +10.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-3.1%
TTM net income over average of 2025-06-28 and 2026-07-04
Return on assets USNA
| FY Jan 2026 | +1.4% |
| FY Dec 2024 | +6.1% |
| FY Dec 2023 | +10.4% |
| FY Dec 2022 | +11.8% |
| FY Jan 2022 | +19.1% |
| Jul 2026 | -3.1% |
| Apr 2026 | +1.2% |
| Jan 2026 | +1.4% |
| Sep 2025 | +2.4% |
| Jun 2025 | +5.0% |
| Mar 2025 | +5.1% |
| Dec 2024 | +6.1% |
| Sep 2024 | +8.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate 1253%, not meaningful
Return on invested capital USNA
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Jan 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-0.2%
operating income (EBIT proxy) over average of 2025-06-28 and 2026-07-04 minus current liabilities
Return on capital employed USNA
| FY Jan 2026 | +6.1% |
| FY Dec 2024 | +11.8% |
| FY Dec 2023 | +19.3% |
| FY Dec 2022 | +24.7% |
| FY Jan 2022 | +38.3% |
| Jul 2026 | -0.2% |
| Apr 2026 | +5.8% |
| Jan 2026 | +6.1% |
| Sep 2025 | +7.2% |
| Jun 2025 | +9.9% |
| Mar 2025 | +10.2% |
| Dec 2024 | +11.8% |
| Sep 2024 | +15.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing USNA
| FY Jan 2026 | 34.71x |
| FY Dec 2024 | 16.30x |
| FY Dec 2023 | 16.24x |
| FY Dec 2022 | 14.82x |
| FY Jan 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | 35.21x |
| Jan 2026 | 34.71x |
| Sep 2025 | 32.42x |
| Jun 2025 | 17.29x |
| Mar 2025 | 15.26x |
| Dec 2024 | 16.30x |
| Sep 2024 | 13.40x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value USNA
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Jan 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+6.1%
TTM free cash flow over market value at close 2026-10-27
FCF yield USNA
| FY Jan 2026 | +2.4% |
| FY Dec 2024 | +7.5% |
| FY Dec 2023 | +5.5% |
| FY Dec 2022 | +9.2% |
| FY Jan 2022 | +5.5% |
| Jul 2026 | +4.0% |
| Apr 2026 | +0.9% |
| Jan 2026 | +2.4% |
| Sep 2025 | +3.6% |
| Jun 2025 | +8.8% |
| Mar 2025 | +9.4% |
| Dec 2024 | +7.5% |
| Sep 2024 | +9.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing USNA
| FY Jan 2026 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Jan 2022 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2026-01 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $925.3M | $854.5M | $921.0M | $998.6M |
| Gross profit | $724.4M | $693.3M | $744.3M | $804.7M |
| Operating income | $37.4M | $66.3M | $93.1M | $107.6M |
| Net income | $10.8M | $42.0M | $63.8M | $69.3M |
| EPS (diluted) | 0.58 | 2.19 | 3.30 | 3.59 |
| Operating cash flow | $22.3M | $61.0M | $70.6M | $103.9M |
| Cash | $158.4M | $181.8M | $330.4M | $288.4M |
| Buybacks | $27.5M | $9.4M | $11.6M | $25.4M |
SEC XBRL, fiscal years, as known on 2026-10-28
USNA Stock Sonar score 5/7 axes
Find similar shapesCompareUSNA ranks highest on profitability (82nd percentile) and growth (57th), and lowest on insider conviction (20th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
USNA filings, in plain words
Are Usana Health Sciences insiders buying or selling USNA?
In the 180 days to 2026-10-28, Usana Health Sciences insiders were net sellers, a net $619.0K across purchases and sales reported on Form 4, by 6 sellers.
Read the full summary
In the 180 days to 2026-10-28, Usana Health Sciences insiders were net sellers of USNA, a net $619.0K across purchases and sales reported on Form 4 by 6 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
